Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
A phase 2 trial of Quizartinib in acute myeloid leukaemia, run by Daiichi Sankyo, now recruiting.
Overview
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission is a phase 2 interventional study registered as NCT06824168 by Daiichi Sankyo, with 130 participants planned, started 2025-07-18 and due to reach its primary completion in 2028-06-06. Interventions recorded: Quizartinib High Dose and Quizartinib Low Dose.
Similar pages
not linked directly; found by shared links- TrialSafety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
Shares Quizartinib, Daiichi Sankyo, Acute myeloid leukaemia and the tag pipeline.
- TrialFirst-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Shares Daiichi Sankyo and the tag pipeline.
- TrialA First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Shares Daiichi Sankyo and the tag pipeline.
- TrialMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialPhase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialClinical Study of U32 in Patients With Acute Myeloid Leukemia
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Shares Daiichi Sankyo and the tag pipeline.
- TrialA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Shares Daiichi Sankyo and the tag pipeline.